Publikasi Scopus FKUI 2021 per tanggal 31 Agustus 2021 (582 artikel)

Tamara A., Coulson D.J., Latief J.S., Bakhashab S., Weaver J.U.
57205305387;57219221240;57219224500;56418579000;57203055590;
Upregulated anti-angiogenic miR-424-5p in type 1 diabetes (model of subclinical cardiovascular disease) correlates with endothelial progenitor cells, CXCR1/2 and other parameters of vascular health
2021
Stem Cell Research and Therapy
12
1
249
Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom; Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, 80218, Saudi Arabia; Department of Diabetes, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, NE9 6SH, United Kingdom; Vascular Biology and Medicine Theme, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom
Tamara, A., Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Coulson, D.J., Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom; Latief, J.S., Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia; Bakhashab, S., Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, 80218, Saudi Arabia; Weaver, J.U., Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom, Department of Diabetes, Queen Elizabeth Hospital, Gateshead, Newcastle upon Tyne, NE9 6SH, United Kingdom, Vascular Biology and Medicine Theme, Newcastle University, Newcastle upon Tyne, NE2 4HH, United Kingdom
Background: In spite of clinical progress, cardiovascular disease (CVD) remains the predominant cause of mortality worldwide. Overexpression studies in animals have proven miR-424-5p to have anti-angiogenic properties. As type 1 diabetes mellitus (T1DM) without CVD displays endothelial dysfunction and reduced circulating endothelial progenitor cells (cEPCs), it offers a model of subclinical CVD. Therefore, we explored miR-424-5p, cytokines and vascular health in T1DM. Methods: Twenty-nine well-controlled T1DM patients with no CVD and 20-matched controls were studied. Cytokines IL8, TNF-α, IL7, VEGF-C, cEPCs/CD45dimCD34+CD133+ cells and ex-vivo proangiogenic cells (PACs)/fibronectin adhesion assay (FAA) were measured. MiR-424-5p in plasma and peripheral blood mononuclear cells (PBMC) along with mRNAs in PBMC was evaluated. Results: We found an elevation of IL7 (p = 0.008), IL8 (p = 0.003), TNF-α (p = 0.041), VEGF-C (p = 0.013), upregulation of mRNA CXCR1 (p = 0.009), CXCR2 (p < 0.001) and reduction of cEPCs (p < 0.001), PACs (p < 0.001) and FAA (p = 0.017) in T1DM. MiR-424-5p was upregulated in T1DM in PBMC (p < 0.001). MiR-424-5p was negatively correlated with cEPCs (p = 0.006), PACs (p = 0.005) and FAA (p < 0.001) and positively with HbA1c (p < 0.001), IL7 (p = 0.008), IL8 (p = 0.017), VEGF-C (p = 0.007), CXCR1 (p = 0.02) and CXCR2 (p = 0.001). ROC curve analyses showed (1) miR-424-5p to be a biomarker for T1DM (p < 0.001) and (2) significant upregulation of miR-424-5p, defining subclinical CVD, occurred at HbA1c of 46.5 mmol/mol (p = 0.002). Conclusion: We validated animal research on anti-angiogenic properties of miR-424-5p in T1DM. MiR-424-5p may be a biomarker for onset of subclinical CVD at HbA1c of 46.5 mmol/mol (pre-diabetes). Thus, miR-424-5p has potential use for CVD monitoring whilst anti-miR-424-5p-based therapies may be used to reduce CVD morbidity/mortality in T1DM. © 2021, The Author(s).
CD45dimCD34+CD133+, CXCR1/2; IL8; MiR-424-5p; T1DM
microRNA; MIRN424 microrna, human; animal; cardiovascular disease; endothelial progenitor cell; genetics; human; insulin dependent diabetes mellitus; mononuclear cell; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Endothelial Progenitor Cells; Humans; Leukocytes, Mononuclear; MicroRNAs
BioMed Central Ltd
17576512
33985567
Article
Q1
1599
2021